PE20230115A1 - Formulaciones de anticuerpos anti-tslp humanos y metodos de uso de los mismos - Google Patents
Formulaciones de anticuerpos anti-tslp humanos y metodos de uso de los mismosInfo
- Publication number
- PE20230115A1 PE20230115A1 PE2022001777A PE2022001777A PE20230115A1 PE 20230115 A1 PE20230115 A1 PE 20230115A1 PE 2022001777 A PE2022001777 A PE 2022001777A PE 2022001777 A PE2022001777 A PE 2022001777A PE 20230115 A1 PE20230115 A1 PE 20230115A1
- Authority
- PE
- Peru
- Prior art keywords
- seq
- amino acid
- set forth
- acid sequence
- sequence set
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39591—Stabilisation, fragmentation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
- C07K16/244—Interleukins [IL]
- C07K16/246—IL-2
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/12—Carboxylic acids; Salts or anhydrides thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
- A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
- C07K16/244—Interleukins [IL]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Genetics & Genomics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Dermatology (AREA)
- Pulmonology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicinal Preparation (AREA)
- Peptides Or Proteins (AREA)
Abstract
Referida a una composicion que comprende mas de 100 mg/mL de un anticuerpo anti-TSLP, un tensioactivo, prolina y un amortiguador, en donde el anticuerpo anti-TSLP comprende: (A) un dominio variable de cadena ligera que comprende: (i) una secuencia de CDR1 de cadena ligera que comprende la secuencia de aminoacidos establecida en la SEQ ID NO:3; (ii) una secuencia de CDR2 de cadena ligera que comprende la secuencia de aminoacidos establecida en la SEQ ID NO:4; y (iii) una secuencia de CDR3 de cadena ligera que comprende la secuencia de aminoacidos establecida en la SEQ ID NO:5; y (B) un dominio variable de cadena pesada que comprende: (i) una secuencia de CDR1 de cadena pesada que comprende la secuencia de aminoacidos establecida en la SEQ ID NO:6; (ii) una secuencia de CDR2 de cadena pesada que comprende la secuencia de aminoacidos establecida en la SEQ ID NO:7; y (iii) una secuencia de CDR3 de cadena pesada que comprende la secuencia de aminoacidos establecida en la SEQ ID NO:8. Dicha composicion es util en el tratamiento de enfermedades inflamatorias.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202062978201P | 2020-02-18 | 2020-02-18 | |
| PCT/US2021/018561 WO2021168100A1 (en) | 2020-02-18 | 2021-02-18 | Formulations of human anti-tslp antibodies and methods of using the same |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PE20230115A1 true PE20230115A1 (es) | 2023-01-27 |
Family
ID=74860588
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PE2022001777A PE20230115A1 (es) | 2020-02-18 | 2021-02-18 | Formulaciones de anticuerpos anti-tslp humanos y metodos de uso de los mismos |
Country Status (19)
| Country | Link |
|---|---|
| US (1) | US20230081261A1 (es) |
| EP (1) | EP4106811A1 (es) |
| JP (1) | JP2023513833A (es) |
| KR (1) | KR20220143699A (es) |
| CN (1) | CN115151276A (es) |
| AR (1) | AR121368A1 (es) |
| AU (1) | AU2021221998A1 (es) |
| BR (1) | BR112022016456A2 (es) |
| CA (1) | CA3167975A1 (es) |
| CL (1) | CL2022002251A1 (es) |
| CO (1) | CO2022013251A2 (es) |
| CR (1) | CR20220465A (es) |
| IL (1) | IL295511A (es) |
| JO (1) | JOP20220193A1 (es) |
| MX (1) | MX2022010120A (es) |
| PE (1) | PE20230115A1 (es) |
| TW (1) | TW202144004A (es) |
| UY (1) | UY39089A (es) |
| WO (1) | WO2021168100A1 (es) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP4145105A1 (de) * | 2021-09-06 | 2023-03-08 | Anacyte Laboratories GmbH | Lösung für die asservierung von zellen |
| WO2023040999A1 (zh) * | 2021-09-18 | 2023-03-23 | 江苏康宁杰瑞生物制药有限公司 | 包含pd-l1抗原结合片段的组合物及其用途 |
| CN116251181B (zh) * | 2021-12-02 | 2023-09-22 | 北京东方百泰生物科技股份有限公司 | 一种抗tslp单克隆抗体的注射制剂 |
| WO2024092064A1 (en) * | 2022-10-26 | 2024-05-02 | Amgen Inc. | Anti-tslp antibody compositions and uses thereof |
| WO2024146630A1 (zh) * | 2023-01-06 | 2024-07-11 | 江苏恒瑞医药股份有限公司 | 一种tslp抗体治疗哮喘的方法 |
Family Cites Families (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| GB8823869D0 (en) | 1988-10-12 | 1988-11-16 | Medical Res Council | Production of antibodies |
| US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
| ES2246502T3 (es) | 1990-08-29 | 2006-02-16 | Genpharm International, Inc. | Animales no humanos transgenicos capaces de producir anticuerpos heterologos. |
| US7982016B2 (en) | 2007-09-10 | 2011-07-19 | Amgen Inc. | Antigen binding proteins capable of binding thymic stromal lymphopoietin |
| US8359965B2 (en) | 2007-09-17 | 2013-01-29 | Oxford J Craig | Apparatus and method for broad spectrum radiation attenuation |
| UY32038A (es) | 2008-08-08 | 2010-03-26 | Glaxo Wellcome Mfg Pte Ltd | Inmunoblobulinas anti-cd127 y sus usos |
| NZ599761A (en) | 2009-11-04 | 2014-04-30 | Merck Sharp & Dohme | Engineered anti-tslp antibody |
| TW201201840A (en) | 2010-07-15 | 2012-01-16 | Hoffmann La Roche | Antibodies specifically binding to human TSLPR and methods of use |
| AT510032B1 (de) | 2010-11-30 | 2012-01-15 | Steiner Erwin Ing | Montageeinrichtung für fassadenelemente |
| US9100245B1 (en) | 2012-02-08 | 2015-08-04 | Amazon Technologies, Inc. | Identifying protected media files |
| US9306926B2 (en) | 2013-03-15 | 2016-04-05 | Brian A. Truong | User authentication using unique hidden identifiers |
| AR103891A1 (es) | 2015-03-11 | 2017-06-14 | Glaxosmithkline Ip Dev Ltd | Proteínas de unión a tslp, ácido nucleico aislado que la codifica, vector y célula hospedadora que lo comprenden, método para producir dicha proteína, su uso para fabricar un medicamento, composición farmacéutica y kit que la comprenden |
| MY186352A (en) | 2015-09-09 | 2021-07-15 | Novartis Ag | Thymic stromal lymphopoietin (tslp)-binding antibodies and methods of using the antibodies |
| JOP20190243A1 (ar) * | 2017-04-12 | 2019-10-13 | Medimmune Llc | علاج الربو بجسم مضاد لـ tslp |
| WO2018200533A1 (en) * | 2017-04-28 | 2018-11-01 | Amgen Inc. | Excipients to reduce the viscosity of antibody formulations and formulation compositions |
| JP7200134B2 (ja) | 2017-06-08 | 2023-01-06 | アムジエン・インコーポレーテツド | トルク駆動式薬物送達デバイス |
| WO2019094138A1 (en) | 2017-11-10 | 2019-05-16 | Amgen Inc. | Plungers for drug delivery devices |
| CA3093699A1 (en) | 2018-03-13 | 2019-09-19 | Amgen Inc. | Methods for the preparation of trypsin-resistant polypeptides for mass spectrometric analysis |
| EP3866890A1 (en) | 2018-10-15 | 2021-08-25 | Amgen Inc. | Drug delivery device having damping mechanism |
| SG11202101824VA (en) | 2018-10-15 | 2021-03-30 | Amgen Inc | Platform assembly process for drug delivery device |
-
2021
- 2021-02-18 BR BR112022016456A patent/BR112022016456A2/pt unknown
- 2021-02-18 MX MX2022010120A patent/MX2022010120A/es unknown
- 2021-02-18 US US17/760,470 patent/US20230081261A1/en active Pending
- 2021-02-18 AR ARP210100423A patent/AR121368A1/es unknown
- 2021-02-18 JP JP2022549318A patent/JP2023513833A/ja active Pending
- 2021-02-18 IL IL295511A patent/IL295511A/en unknown
- 2021-02-18 CA CA3167975A patent/CA3167975A1/en active Pending
- 2021-02-18 AU AU2021221998A patent/AU2021221998A1/en active Pending
- 2021-02-18 JO JOP/2022/0193A patent/JOP20220193A1/ar unknown
- 2021-02-18 UY UY0001039089A patent/UY39089A/es unknown
- 2021-02-18 CR CR20220465A patent/CR20220465A/es unknown
- 2021-02-18 KR KR1020227031575A patent/KR20220143699A/ko unknown
- 2021-02-18 CN CN202180015035.0A patent/CN115151276A/zh active Pending
- 2021-02-18 PE PE2022001777A patent/PE20230115A1/es unknown
- 2021-02-18 WO PCT/US2021/018561 patent/WO2021168100A1/en active Application Filing
- 2021-02-18 TW TW110105518A patent/TW202144004A/zh unknown
- 2021-02-18 EP EP21710848.9A patent/EP4106811A1/en active Pending
-
2022
- 2022-08-18 CL CL2022002251A patent/CL2022002251A1/es unknown
- 2022-09-16 CO CONC2022/0013251A patent/CO2022013251A2/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CN115151276A (zh) | 2022-10-04 |
| TW202144004A (zh) | 2021-12-01 |
| IL295511A (en) | 2022-10-01 |
| JOP20220193A1 (ar) | 2023-01-30 |
| AR121368A1 (es) | 2022-06-01 |
| CR20220465A (es) | 2023-03-30 |
| UY39089A (es) | 2021-08-31 |
| US20230081261A1 (en) | 2023-03-16 |
| MX2022010120A (es) | 2022-09-05 |
| KR20220143699A (ko) | 2022-10-25 |
| BR112022016456A2 (pt) | 2022-10-04 |
| CA3167975A1 (en) | 2021-08-26 |
| CL2022002251A1 (es) | 2023-04-14 |
| EP4106811A1 (en) | 2022-12-28 |
| JP2023513833A (ja) | 2023-04-03 |
| CO2022013251A2 (es) | 2022-12-20 |
| WO2021168100A1 (en) | 2021-08-26 |
| AU2021221998A1 (en) | 2022-09-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PE20230115A1 (es) | Formulaciones de anticuerpos anti-tslp humanos y metodos de uso de los mismos | |
| PE20110668A1 (es) | Anticuerpos anti-linfopoyetina estromal timica (anti-tslp) | |
| CO6231009A2 (es) | Anticuerpos ox40 antagonistas y su uso en el tratamiento de enfermedades inflamatorias y autoinmunes | |
| PE20091205A1 (es) | Anticuerpo anti-receptor de il-6 | |
| PE20240813A1 (es) | Formulaciones estables de anticuerpos contra el receptor de muerte programada 1 (pd-1) y metodo para su uso | |
| PE20140882A1 (es) | Anticuerpos neutralizantes de citomegalovirus humano | |
| PE20070998A1 (es) | Moleculas de anticuerpo que tienen especificidad para la il-6-humana | |
| PE20080214A1 (es) | Moleculas de anticuerpo que se unen a la il-17 humana | |
| AR046639A1 (es) | Combinaciones terapeuticas de anticuerpo anti- igfr1 | |
| PE20220220A1 (es) | Anticuerpos y fragmentos de anticuerpo para la conjugacion sitio-especifica | |
| PE20091449A1 (es) | Proteinas de union a antigenos | |
| ES2721753T3 (es) | Anticuerpos contra IL-6 y usos de los mismos | |
| EA199800563A1 (ru) | Антагонисты гормона, высвобождающего гонадотропин | |
| SV2006002174A (es) | Composicion de anticuerpo her2 | |
| EA200401522A1 (ru) | Противотуберкулёзный препарат: композиции и способы | |
| PE20120429A1 (es) | Proteinas de enlace de miostatina | |
| PE20121579A1 (es) | Proteinas de enlace al antigeno il-23 humanas | |
| AR088579A1 (es) | Formulaciones de anticuerpos | |
| PE20030065A1 (es) | Metodos para administrar anticuerpos anti-tnfalfa | |
| PE20050925A1 (es) | Anticuerpo recombinante humanizado anti-interleuquina 10 | |
| ECSP066294A (es) | Un conjugado citotóxico ca6 antígeno-específico y métodos para utilizar el mismo | |
| PE20061324A1 (es) | Anticuerpos anti-il-6, composiciones, metodos y usos | |
| PE20120816A1 (es) | Composiciones que comprenden anticuerpos de dickkopf-1 | |
| AR003427A1 (es) | Péptidos relacionados con dolastatina, procedimiento para prepararlos, composiciones farmacéuticas que los contienen y el uso de los mismos para la preparación de dichas composiciones farmacéuticas. | |
| AR061986A1 (es) | Agentes inductores de muerte celular |